

12 April 2026

[submitted electronically via: SLegislation@rilegislature.gov]

The Honorable Chair Murray, Senate Health & Human Services
State House
82 Smith Street
Providence, RI 02903

RE: SUPPORT – S2112 - Matt Federico Diabetic Safety Act - Glucagon

Dear Chair Murray and members of the Committee:

I am submitting this letter to state my complete support of S2112. This act would require group health plans and health insurance issuers to provide prescription benefits to cover at least one type of glucagon autoinjector, nasal spray, or formulation which does not require reconstitution to treat hypoglycemia with two (2) glucagon auto-injectors every plan year. Further, no copayment or deductible would be required to obtain prescribed glucagon medications.

As a diabetes outpatient educator, I see firsthand how lack of access to emergency medications like glucagon puts people living with diabetes at unnecessary risk. Guaranteeing two no-cost glucagon devices annually would remove a critical barrier to care and support evidence-based management for individuals using insulin. Ensuring patients have timely access to a life-saving medication is essential for safety, peace of mind, and survival.

Sincerely,



Ginger Lemay, PharmD, CDOE, CVDOE

Clinical Professor

PGY1 Community-Based Residency Program Director

University of Rhode Island College of Pharmacy

President, Rhode Island Pharmacists Association, 2022-2023

Practice Sites:

Walgreens Pharmacy, Community Pharmacist

Visiting Nurse Home & Hospice, Transition of Care Pharmacist